الفهرس Only 14 pages are availabe for public view
 |  | from | 212 |  |  |
| | | from | 212 | | |
Abstract
Non steroidal anti-inflammatory drugs (NSAIDs) got high importance as they inhibit the progression of cancer especially colon cancer. They can reduce the size of current tumor; increase the efficiency of anticancer agents and radiotherapy. However, long-term uses of non-selective NSAIDs can lead to gastrointestinal toxicity from sustained inhibition COX. Lornoxicam is a non steroidal anti-inflammatory drug of oxicam class and it has the same side effects of this group when taken orally and has a relatively short plasma half-life (3 to 4 h) which makes it a good candidate for colon targeting. It could avoid the systemic side effects, enhance its low oral bioavailability due to hepatic first pass metabolism and delay drug release to target the colon and lower the extent of colorectal carcinomas. The present study was carried out to develop oral colon targeted drug delivery systems for Lornoxicam utilizing many strategies as pH sensitive, pressure dependent, microbially triggered and time dependent enteric coating of granules, tablet and beads